Glial Tumors, Pulmonary Embolism (Diagnosis), Thrombosis
Conditions
Keywords
Glial tumors, Thrombosis, thromboelastometry
Brief summary
The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.
Detailed description
The main hypothesis is Adult patients with glial tumors who present a pattern of hypercoagulability in laboratory parameters and/or thromboelastometry have a higher incidence of thromboembolic events and lower survival compared with patients without a hypercoagulability pattern.
Interventions
DIAGNOSTIC_TESTThromboelastometry values: EXTEM CT, MCF, α-angle below the lower limit of normal. Measurement obtained after anesthetic induction. - PT, aPTT, fibrinogen, platelet count. - Thrombin generation. -
* Molecular markers: including Next-Generation Sequencing (Oncomine Comprehensive Assay v3 or Oncomine Precision Assay) when available. * MGMT promoter methylation status.
Sponsors
Fundacion Clinic per a la Recerca Biomédica
Hospital Clinic of Barcelona
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent
Exclusion criteria
* Patients under 18 years of age. * Emergency surgery. * Patients receiving antiplatelet or anticoagulant treatment. * Patients with known hematologic diseases associated with coagulation abnormalities. Examples include: * Congenital or acquired platelet function disorders. * Congenital deficiency of protein C or protein S. * Deficiency of coagulation factors II, V, VII, X, XII. * Glanzmann thrombasthenia. * Hemophilia A, B, or C. * Idiopathic thrombocytopenic purpura (ITP). * von Willebrand disease (types I, II, and III). * Systemic diseases that cause significant coagulation time alterations: * Prothrombin time \< 60%. * Activated partial thromboplastin time (aPTT) \> 50 seconds. * Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Thromboembolic events | 3 months post-surgery | Any newly developed thrombotic event (or acute worsening of a previous one) occurring within: Pulmonary embolism, stroke, venous trombosis |
Countries
Spain
Contacts
CONTACTPaola A Hurtado, MD, PhD
PRINCIPAL_INVESTIGATORPaola Hurtado Restrepo, MD, PhD
Hospital Clinic of Barcelona
Outcome results
None listed